UnitedHealthcare respiratory nucleic acid testing Coverage

Coverage Criteria

Outpatient multiplex panel coverage rule

Not medically necessary for outpatient use

Primary rule: Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary due to insufficient evidence of efficacy for all indications.6+ targets

Applies to outpatient setting per policy statement.

Medically Necessary / Appropriate Use

Covered when consistent with professional guidelines and patient risk/setting considerations

Appropriate clinical scenarios: Testing is supported for hospitalized patients (including ICU), immunocompromised or transplant recipients, hematology/oncology patients, and pediatric patients with underlying illness; consider testing for patients with severe disease or when results are expected to influence management.

Derived from ASM, ATS, IDSA, and joint AMP/ASM/IDSA/PASCV guidance

Limited/Not Routinely Recommended

Coverage limited or not routinely supported when ALL of the following apply

Routine outpatient noninfluenza multiplex testing: Adult outpatients without high‑risk conditions or severe illness; testing is for noninfluenza viral pathogens where results are unlikely to change management.

ATS recommends against routine outpatient nucleic acid-based testing for noninfluenza viruses; evidence suggests limited additional benefit of multiplex panels versus targeted influenza testing

This medical policy applies only to services provided in the state of Pennsylvania. Requests for respiratory pathogen testing that do not meet the criteria set forth in this policy will be evaluated on a case‑by‑case basis in accordance with Pennsylvania Code, Title 55, Chapter 1101.

Professional guidance emphasizes selective use of nucleic acid–based testing in adult outpatients. The American Thoracic Society (ATS) issues a conditional recommendation (very low‑quality evidence) to not perform routine outpatient nucleic acid–based testing for viral pathogens other than influenza. Clinical evidence from outpatient cohort studies also suggests that targeted testing for influenza may be sufficient in many outpatient settings, and that multiplex testing for noninfluenza viruses has not consistently demonstrated additional impact on management.

Respiratory pathogen panel testing that includes six or more targets performed in the outpatient setting is considered unproven and not medically necessary due to insufficient evidence of benefit; such panels are therefore not supported for routine outpatient use.

Multiplex testing in average‑risk adult outpatients—particularly for noninfluenza viral pathogens—should be limited when results are unlikely to change clinical management. Outpatient studies indicate detection of noninfluenza viruses does not consistently reduce antibiotic use or alter treatment compared with targeted influenza testing, supporting selective rather than routine multiplex use.

Covered Indications and Appropriate Settings

Evaluation when conventional tests fail or rapid identification needed

Covered in complex or inpatient settings when standard diagnostics are non-diagnostic or rapid, broad pathogen identification could change management

When conventional tests fail or rapid ID needed: Use metagenomic next‑generation sequencing (mNGS) or comprehensive multiplex panels for evaluation of respiratory infections when conventional diagnostic tests are negative or inconclusive, or when rapid identification of an unexpected or atypical pathogen would alter treatment or infection control.

Evidence suggests mNGS and some panels are promising particularly in immunocompromised patients and complex inpatient cases; outpatient utility remains insufficiently proven

Populations considered appropriate candidates (hospitalized, ICU, immunocompromised, hematology/oncology, pediatric with comorbidity)

Populations considered appropriate candidates

Appropriate patient populations: Hospitalized patients (including ICU), immunocompromised or transplant recipients, hematology/oncology patients, and pediatric patients with underlying illness are appropriate candidates for multiplex respiratory panel testing when results will influence management.

Not Covered / Not Medically Necessary

Multiplex respiratory pathogen panels that include six or more targets performed in the outpatient setting are not medically necessary and are not covered under this policy.

Routine multiplex testing for noninfluenza viral pathogens in average‑risk adult outpatients is not routinely supported. The ATS guideline provides a conditional recommendation against routine outpatient nucleic acid–based testing for noninfluenza viruses, and outpatient clinical data question whether multiplex panels add meaningful management benefit beyond targeted influenza testing.

Coding and Test Identifiers

Applicable procedure codesmixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
87632	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87633	Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (e.g., adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

FDA product codes (informational)mixed

OCC, QDS, QDP, QOF

FDA product codes referenced for respiratory viral panel devices.

Provider Actions and Billing Guidance

Prior Authorization

Pennsylvania application and outpatient panel prior review

This policy applies only to services in Pennsylvania. Any requests for services that do not meet criteria set in the Pennsylvania application (PARP) will be evaluated case-by-case. Providers must follow Pennsylvania Exceptions (Pennsylvania Code, Title 55, Chapter 1101) when submitting outpatient respiratory pathogen panel testing.

Policy applies only to Pennsylvania.
Outpatient panels subject to Pennsylvania PARP review.

Prior Authorization

Plan-specific authorization

Check the member's benefit plan and applicable federal, state, or contractual requirements before ordering tests. Prior authorization may be required per the member's plan; confirm coverage and any prior authorization requirements with UnitedHealthcare and obtain authorization when required.

Verify member-specific benefits and prior authorization requirements.
In the event of conflicts, federal/state/contractual requirements govern coverage.

Ordering Requirements

Step Therapy

Order based on clinical context; consider targeted testing first

Order testing based on clinical context; targeted testing may be sufficient and is preferred unless there is clinical justification for multiplex testing.

Clinical evidence suggests targeted testing (e.g., influenza-only) may suffice for many outpatients.
Document why multiplex testing is necessary when used in outpatient settings.

Prior Authorization

Order only when results will affect management (hospitalized/high‑risk/severe cases)

Order multiplex or comprehensive testing only when results will influence management—such as for hospitalized/ICU patients, high‑risk or immunocompromised patients, or patients with severe disease—and verify member plan and state requirements before ordering.

Appropriate candidates include hospitalized/ICU patients, transplant or hematology/oncology patients, and pediatric patients with underlying illness.
Confirm that testing is expected to change treatment or infection control decisions prior to ordering.

Frequency Limits

Frequency limits

Frequency limits statedNo explicit frequency limits are stated in this document segment.

Panel size guidancePolicy identifies outpatient respiratory pathogen panels of six or more targets as unproven and not medically necessary, but does not specify a repeat interval.

Coverage determination basisFrequency/interval determinations are to be guided by medical necessity and applicable federal, state, or contractual requirements; no numeric limits provided.

Frequency limits (placeholder)

Placeholder noteNo frequency limit content provided in the source; none available to specify here.

Action for providersWhen ordering, document clinical rationale since no preset frequency rules are defined in this policy.

Definitions

Multiplex PCR assays

DefinitionMultiplex PCR assays identify predefined microbial genetic material (RNA or nucleic acids) in respiratory specimens using multiplex reverse transcription–PCR to detect multiple targets simultaneously.

CharacteristicsDesigned to detect multiple viral and/or bacterial targets from a single specimen; each analyte typically reported as detected/not detected.

Interpretation caveatDetection does not confirm viable pathogen or active replication; results require clinical correlation.

Metagenomic next-generation sequencing (mNGS)

DefinitionMetagenomic next-generation sequencing (mNGS) is unbiased sequencing of all nucleic acid in a sample to identify genes from multiple organisms within a specimen.

Intended use

Background and Evidence Summary

Molecular assays such as reverse transcription–polymerase chain reaction and other nucleic acid amplification tests detect microbial nucleic acids (RNA or DNA) in respiratory specimens. Metagenomic next‑generation sequencing (mNGS) performs unbiased sequencing of nucleic acids in a sample to identify genetic material from multiple organisms. Detection of nucleic acid does not necessarily indicate viable pathogen or active replication; larger multiplex approaches can identify multiple agents, may detect coinfections, and show variable accuracy across targets, which can complicate clinical interpretation and the evidence for improved outcomes in outpatient settings.

OpenPayer

Respiratory Pathogen Nucleic Acid Detection Testing (for Pennsylvania Only)

Coverage Criteria

Covered Indications and Appropriate Settings

Not Covered / Not Medically Necessary

Coding and Test Identifiers

Provider Actions and Billing Guidance

Ordering Requirements

Frequency Limits

Definitions

Background and Evidence Summary